Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
about
Spotlight on decitabine for myelodysplastic syndromes in Chinese patientsThe hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy aloneThe priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution.Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemiaConsolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
P2860
Q26778454-F3F02D0B-2750-4795-849C-4046774AE071Q36545229-CDC1871E-0FE8-4688-89C6-0E959EAD1425Q37742267-6FB7B135-C17B-40B8-9E69-8E9C44515C83Q38640497-028DA240-2290-4781-B052-4B11B3C205FCQ39295844-40169D00-D37A-4844-A657-B7EDDDE13A5EQ40055082-B3B9D7A4-F457-4B0B-92FF-B104130E9D82Q40236553-7E4CFA8B-A321-488C-BB56-FE3E95B9E42DQ40548451-4E6D6A6E-38D6-4BB8-9D81-154DB62D3838Q41593326-545AFE86-DB3C-46BB-860A-49B9E7C2678CQ47770899-74B6F0FD-1181-4B3E-B9D1-E17E678B3378Q57815598-30D3E278-834D-4027-8973-2C4A559D548E
P2860
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of decitab ...... ts with acute myeloid leukemia
@ast
Efficacy and safety of decitab ...... ts with acute myeloid leukemia
@en
type
label
Efficacy and safety of decitab ...... ts with acute myeloid leukemia
@ast
Efficacy and safety of decitab ...... ts with acute myeloid leukemia
@en
prefLabel
Efficacy and safety of decitab ...... ts with acute myeloid leukemia
@ast
Efficacy and safety of decitab ...... ts with acute myeloid leukemia
@en
P2093
P2860
P356
P1433
P1476
Efficacy and safety of decitab ...... ts with acute myeloid leukemia
@en
P2093
Hongxia Qiu
Huayuan Zhu
Jiahua Ding
Jianfeng Zhou
Jianmin Wang
Jianyong Li
P2860
P304
P356
10.18632/ONCOTARGET.3361
P407
P577
2015-03-01T00:00:00Z